158 related articles for article (PubMed ID: 7901342)
1. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.
Huizing MT; Keung AC; Rosing H; van der Kuij V; ten Bokkel Huinink WW; Mandjes IM; Dubbelman AC; Pinedo HM; Beijnen JH
J Clin Oncol; 1993 Nov; 11(11):2127-35. PubMed ID: 7901342
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial.
Huizing MT; Vermorken JB; Rosing H; ten Bokkel Huinink WW; Mandjes I; Pinedo HM; Beijnen JH
Ann Oncol; 1995 Sep; 6(7):699-704. PubMed ID: 8664192
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
Huizing MT; van Warmerdam LJ; Rosing H; Schaefers MC; Lai A; Helmerhorst TJ; Veenhof CH; Birkhofer MJ; Rodenhuis S; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1997 May; 15(5):1953-64. PubMed ID: 9164207
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 1-hour and 3-hours paclitaxel infusion pharmacokinetics: results from a randomized trial.
Mross K; Häring B; Holländer N; Mielke S; Behringer D; Massing U; Unger C
Onkologie; 2002 Dec; 25(6):503-8. PubMed ID: 12566894
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.
Huizing MT; Giaccone G; van Warmerdam LJ; Rosing H; Bakker PJ; Vermorken JB; Postmus PE; van Zandwijk N; Koolen MG; ten Bokkel Huinink WW; van der Vijgh WJ; Bierhorst FJ; Lai A; Dalesio O; Pinedo HM; Veenhof CH; Beijnen JH
J Clin Oncol; 1997 Jan; 15(1):317-29. PubMed ID: 8996159
[TBL] [Abstract][Full Text] [Related]
6. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.
Gianni L; Kearns CM; Giani A; Capri G; Viganó L; Lacatelli A; Bonadonna G; Egorin MJ
J Clin Oncol; 1995 Jan; 13(1):180-90. PubMed ID: 7799018
[TBL] [Abstract][Full Text] [Related]
7. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors.
Sonnichsen DS; Hurwitz CA; Pratt CB; Shuster JJ; Relling MV
J Clin Oncol; 1994 Mar; 12(3):532-8. PubMed ID: 7907130
[TBL] [Abstract][Full Text] [Related]
8. PAC fixed dose: pharmacokinetics of a 1-hour paclitaxel infusion and comparison to BSA-normalized drug dosing.
Mross K; Holländer N; Frost A; Unger C; Ziroli V; Massing U
Onkologie; 2006 Oct; 29(10):444-50. PubMed ID: 17028453
[TBL] [Abstract][Full Text] [Related]
9. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.
Fennelly D; Aghajanian C; Shapiro F; O'Flaherty C; McKenzie M; O'Connor C; Tong W; Norton L; Spriggs D
J Clin Oncol; 1997 Jan; 15(1):187-92. PubMed ID: 8996141
[TBL] [Abstract][Full Text] [Related]
10. Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel.
Rischin D; Webster LK; Millward MJ; Linahan BM; Toner GC; Woollett AM; Morton CG; Bishop JF
J Natl Cancer Inst; 1996 Sep; 88(18):1297-301. PubMed ID: 8797769
[TBL] [Abstract][Full Text] [Related]
11. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial.
de Jong J; Geijssen GJ; Munniksma CN; Vermorken JB; van der Vijgh WJ
J Clin Oncol; 1992 Dec; 10(12):1897-906. PubMed ID: 1453205
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
Miller AA; Rosner GL; Egorin MJ; Hollis D; Lichtman SM; Ratain MJ
Clin Cancer Res; 2004 Dec; 10(24):8325-31. PubMed ID: 15623609
[TBL] [Abstract][Full Text] [Related]
13. A phase II and pharmacokinetic study of weekly 72-h topotecan infusion in patients with platinum-resistant and paclitaxel-resistant ovarian carcinoma.
Rose PG; Gordon NH; Fusco N; Fluellen L; Rodriguez M; Ingalls ST; Hoppel CL
Gynecol Oncol; 2000 Aug; 78(2):228-34. PubMed ID: 10926808
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic study of paclitaxel as a 3-hour infusion in an Indian population: 135 mg/m2 vs. 175 mg/m2.
Dhanikula AB; Panchagnula R; Singh I; Kaur KJ; Kaul CL; Sekhon JS
Methods Find Exp Clin Pharmacol; 2001 Mar; 23(2):93-8. PubMed ID: 11484417
[TBL] [Abstract][Full Text] [Related]
15. Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol).
Beijnen JH; Huizing MT; ten Bokkel Huinink WW; Veenhof CH; Vermorken JB; Giaccone G; Pinedo HM
Semin Oncol; 1994 Oct; 21(5 Suppl 8):53-62. PubMed ID: 7939764
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion.
Panday VR; ten Bokkel Huinink WW; Vermorken JB; Rosing H; Koopman FJ; Swart M; Schellens JH; Beijnen JH
Pharmacol Res; 1999 Jul; 40(1):67-74. PubMed ID: 10378993
[TBL] [Abstract][Full Text] [Related]
17. Nonlinear pharmacokinetics of paclitaxel in ovarian cancer patients.
Ye M; Zhu Z; Fu Q; Shen K; Li DK
Acta Pharmacol Sin; 2000 Jul; 21(7):596-9. PubMed ID: 11360664
[TBL] [Abstract][Full Text] [Related]
18. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
[TBL] [Abstract][Full Text] [Related]
19. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
20. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.
Conte PF; Baldini E; Gennari A; Michelotti A; Salvadori B; Tibaldi C; Danesi R; Innocenti F; Gentile A; Dell'Anna R; Biadi O; Mariani M; Del Tacca M
J Clin Oncol; 1997 Jul; 15(7):2510-7. PubMed ID: 9215819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
